Invokana

Canagliflozin, the active ingredient in Invokana, is a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels.

GNH USA supplies Invokana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Invokana belongs to the SGLT2 inhibitor class and is used to improve glycaemic control in diabetes. - Type 2 diabetes mellitus (monotherapy): reduces fasting plasma glucose and HbA1c levels when used alone. - Type 2 diabetes mellitus (add‑on therapy): provides additional glucose lowering when combined with metformin or other oral agents. - Type 2 diabetes mellitus (renal protection): may slow progression of diabetic kidney disease in eligible patients.

Adverse reactions may occur with canagliflozin therapy.

Common Side Effects: - Genital mycotic infection: itching or discharge in the genital area. - Urinary tract infection: dysuria, frequency, or urgency. - Increased urination: polyuria and related thirst. - Mild hypotension: dizziness or light‑headedness, especially on standing. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Ketoacidosis: metabolic acidosis with elevated ketone bodies. - Acute kidney injury: sudden decline in renal function. - Fournier's gangrene: necrotizing fasciitis of the perineum. - Severe dehydration: marked fluid loss leading to hypotension. - Anaphylactic reaction: life‑threatening allergic response.

When prescribing canagliflozin, several safety considerations are recommended. - Renal function monitoring: assess eGFR before initiation and periodically thereafter. - Ketoacidosis risk: educate patients to recognize symptoms and discontinue if they occur. - Cardiovascular status: evaluate for heart failure or hypotension. - Concomitant diuretics: adjust dosage to avoid excessive volume depletion. - Genital infection hygiene: advise proper personal care to reduce infection risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Canagliflozin may interact with other medicines, requiring attention to dosage and monitoring. Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: heightened hypoglycaemic potential. - Loop diuretics: may exacerbate dehydration and hypotension. Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible additive blood‑pressure lowering effect. - NSAIDs: potential impact on renal function. - Rifampin: may reduce canagliflozin exposure. - Thiazide diuretics: monitor for volume depletion. - Warfarin: occasional alteration of INR, require closer monitoring.